Asuragen, Inc.

134 articles about Asuragen, Inc.

• Asuragen, Inc. Launches SuraSeq™ Next Generation Sequencing Services

  4/4/2013

• Asuragen, Inc. Study Finds New Genetic Test Better Predicts Mother's Risk of Having a Child With Fragile X Syndrome

  3/21/2013

• Asuragen, Inc. Collects $7.5 Million Financing

  3/21/2013

• Rolland Carlson, Ph.D. Named CEO of Asuragen, Inc.

  1/7/2013

• Asuragen, Inc. to Present at Upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine

  10/24/2012

• Asuragen, Inc. Grants Armored RNA® Technology License to Becton, Dickinson and Company

  6/19/2012

• Asuragen, Inc. Release: Data Presented at the Annual Meeting of the American Association of Endocrine Surgeons Illustrates the Clinical Utility of miRInform® Thyroid Panel Used in Conjunction with Ultrasound-Guided Fine Needle Aspiration

  5/1/2012

• Asuragen, Inc. Awarded $6.8 Million Commercialization Award from the Cancer Prevention and Research Institute of Texas

  3/30/2012

• FDA Clears Asuragen, Inc.'s RNARetain® Pre-analytical RNA Stabilization Device

  3/22/2012

• Asuragen, Inc. Launches miRInform® Pancreas Test for use on Fine Needle Aspirate Specimens of Pancreatic Masses

  2/17/2012

• Life Technologies Appoints Asuragen, Inc. as a Certified Service Provider for Ion Ion Torrent Systems, Inc.’s Personal Genome Machine

  2/2/2012

• Asuragen, Inc. to Present at Upcoming Association for Molecular Pathology 17th Annual Meeting

  11/15/2011

• Asuragen, Inc. Release: Results of a Multi-Center Study Show MicroRNA-Based Pancreatic Cancer Assay Improves the Diagnostic Accuracy of FNA Cytology

  11/4/2011

• Asuragen, Inc. Release: Results of a Multi-Center Study Show MicroRNA-Based Pancreatic Cancer Assay Improves the Diagnostic Accuracy of FNA Cytology

  11/3/2011

• Asuragen, Inc. Release: MicroRNA Biomarkers in Cyst Fluid May Improve the Management of Pancreatic Cysts

  11/3/2011

• Asuragen, Inc. Launches BCR-ABL1 Calibrator Panels for IS Standardization

  10/31/2011

• Asuragen, Inc. Announces Launch of Xpansion Interpreter™, a Service for AGG Mapping of the Fragile X Gene, in its CAP Accredited CLIA Laboratory

  10/28/2011

• Asuragen, Inc. Announces Launch of Xpansion Interpreter™, a Service for AGG Mapping of the Fragile X Gene, in its CAP Accredited CLIA Laboratory

  10/28/2011

• Asuragen, Inc. Release: Data from Evaluation of Signature(R) LTx Leukemia Test to be Presented at Upcoming Planet XMAP

  9/27/2011

• Asuragen, Inc. and Fragile X Collaborators Report Findings Using a Novel Methylation PCR Technology to Characterize the FMR1 Gene

  6/29/2011